Curious about Zoetis (ZTS) Q1 Performance? Explore Wall Street Estimates for Key Metrics
π Wall Street analysts expect Zoetis (ZTS) to report quarterly earnings of $1.61 per share, representing an 8.8% increase from the previous year.
π° Projected revenue for the quarter is set at $2.3 billion, which would reflect a 3.6% growth compared to the same period last year.
π The consensus EPS estimate has been adjusted upward by 1.1% over the past 30 days, indicating positive reassessment by covering analysts.
π¬ Revenue from contract manufacturing and human health is estimated at $28.94 million with a negligible decline of -0.2% year-over-year.
πΎ Companion animal revenue is projected to reach $1.58 billion, showing a 2.3% increase from the prior-year quarter.
π Livestock sector revenues are estimated at $680.48 million, reflecting a 5.5% growth year-over-year.
π Swine-specific revenue within livestock is forecasted to be $112.11 million, marking a 1% increase from the previous quarter.
π Cattle segment revenues are expected to hit $370.52 million, indicating a 3.5% rise year-over-year.
π Fish-related livestock revenue is projected at $57.00 million, showing a significant 7.6% jump from the prior year.
π U.S. geographic revenues are estimated at $1.20 billion, representing a 1.2% increase year-over-year.
π International revenues are forecasted to reach $1.08 billion, with a strong 6.7% growth rate compared to the previous year.
π U.S.-based livestock revenue is expected to arrive at $221.92 million, reflecting a 5.7% increase from the prior year.
πΎ U.S.-based companion animal revenue is projected at $976.53 million with a slight 0.4% rise year-over-year.
π Zoetis shares have declined by 4.7% over the past month, underperforming the S&P 500 composite which rose 9.5%.
βοΈ Zacks assigns Zoetis a Rank #3 (Hold), suggesting future performance will likely align with the overall market trend.
- Wall Street analysts expect Zoetis (ZTS) to post quarterly earnings of $1.61 per share, indicating an optimistic year-over-year increase of 8.8%.
- Revenues are forecast to reach $2.3 billion, reflecting a positive growth trajectory of 3.6% compared to the prior-year quarter.
- Analyst consensus for EPS estimates has been adjusted upward by 1.1% over the past 30 days, signaling growing investor confidence in the company's performance.
- Companion Animal revenues are projected to reach $1.58 billion, with analysts estimating a solid year-over-year increase of 2.3%.
- Livestock segment shows robust growth potential, with estimated revenues of $680.48 million and a strong year-over-year change of +5.5%.
- International revenue is expected to grow significantly at +6.7% year over year, reaching $1.08 billion, highlighting expansion outside the U.S. market.
- Despite upward adjustments in consensus EPS estimates over the past 30 days, Zoetis shares have underperformed the broader market significantly, recording a -4.7% return versus the Zacks S&P 500 composite's +9.5% change.
- The company currently holds a Zacks Rank #3 (Hold) rating, suggesting limited upside potential compared to top-rated stocks in the list.
- Revenues from Contract Manufacturing & Human Health are projected to decline slightly by -0.2% year over year compared to the prior-year quarter.
- U.S. Companion Animal revenues are expected to remain nearly flat with only a marginal +0.4% increase from the previous period.